<DOC>
	<DOC>NCT02693392</DOC>
	<brief_summary>In the proposed study, hydroalcoholic Fenugreek seed extract will used add-on to the existing therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be evaluated using standard methodology.</brief_summary>
	<brief_title>Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes</brief_title>
	<detailed_description>Trigonella foenum-graecum, commonly known as Fenugreek, is a plant that has been extensively used as a source of antidiabetic compounds, from its seeds, leaves and extracts in different systems of medicine in asia. Fenugreek is traditionally used in India, especially in the Ayurvedic and Unani systems. Preliminary animal and human studies suggest possible hypoglycemic and anti-hyperlipidemic properties of fenugreek seed powder taken orally. In a randomized placebo controlled study conducted by Gupta et al showed that two month treatment with the hydro-alcoholic extract of fenugreek seeds improved glycemic control in 12 non-insulin dependent diabetes mellitus patients. In addition, there was improvement in insulin sensitivity and plasma lipid profile. Fenugreek extract was also well tolerated in diabetic patients. In the proposed study, hydroalcoholic Fenugreek seed extract will used add-on to the existing therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be evaluated using standard methodology.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Fenugreek seed meal</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Patients suffering from Type2 Diabetes of less than 10 years duration Patients with HbA1c &gt;7.0% Patients with fasting plasma glucose not exceeding 180 mg/dL Patients with Negative Urine sugar Patients who are on oral hypoglycaemic agents containing either Metformin or Sulfonylurea or both There should not be any change their in antidiabetic treatment for at least one month Patients with diabetes other than type2 diabetes mellitus Patients with evidence of renal disease (S. Creatinine &gt; 1.5mg/dL) Patients with evidence of liver disease (AST/ALT &gt;3 times of normal Pregnant and lactating mothers and women intending pregnancy Patients who participated in any other clinical trial within the last 30 days Patients with history of any hemoglobinopathy History of intolerance or hypersensitivity to Fenugreek</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fenugreek seed extract</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Blood glucose</keyword>
</DOC>